Assetmark Inc. Boosts Stake in Charles River Laboratories International, Inc. $CRL

Assetmark Inc. boosted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 19.6% in the first quarter, Holdings Channel.com reports. The institutional investor owned 52,387 shares of the medical research company’s stock after acquiring an additional 8,578 shares during the period. Assetmark Inc.’s holdings in Charles River Laboratories International were worth $9,037,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its position in Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after purchasing an additional 1,074 shares during the last quarter. Empowered Funds LLC bought a new position in Charles River Laboratories International during the first quarter valued at $418,000. American Century Companies Inc. lifted its position in Charles River Laboratories International by 41.9% during the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock valued at $830,000 after purchasing an additional 1,616 shares during the last quarter. Brown Advisory Inc. grew its stake in shares of Charles River Laboratories International by 5.1% in the 2nd quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after buying an additional 114 shares in the last quarter. Finally, California Public Employees Retirement System increased its holdings in shares of Charles River Laboratories International by 3.9% in the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after buying an additional 3,198 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

CRL stock opened at $219.91 on Tuesday. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03. The business has a 50-day moving average price of $193.76 and a 200 day moving average price of $186.77. The company has a market capitalization of $10.59 billion, a P/E ratio of -58.49, a PEG ratio of 2.50 and a beta of 1.40. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $237.86.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.10. The company had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of analyst reports. Barclays increased their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a research note on Wednesday, July 1st. Weiss Ratings raised Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 1st. Mizuho increased their price target on Charles River Laboratories International from $192.00 to $230.00 and gave the company a “neutral” rating in a report on Monday, July 13th. Finally, JPMorgan Chase & Co. lowered their price target on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Monday, April 13th. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $220.75.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director James C. Foster sold 75,000 shares of the stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the transaction, the director directly owned 31,596 shares in the company, valued at approximately $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.